Antihemophilic Factor Market size is poised to surpass USD 6 Billion by the end of 2036, growing at a CAGR of 7% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of the antihemophilic factor was USD 3 Billion. The market is experiencing exponential growth due to the need for effective hemophilia treatments amidst high treatment costs. A 2021, study highlights that lifetime treatment costs for severe hemophilia B can reach up to USD 21 million for on-demand fix treatment and USD 23 million for preventive treatment. Research from 2022 further revealed that annual treatment costs between USD 150,000 and USD 300,000, excluding indirect costs like lost productivity. These staggering expenses underscore the demand for more efficient, cost-effective antihemophilic factors.
Factors believed to propel antihemophilic factor market growth include market evolution – trend adaptation, highlighting the importance of quickly adapting to market trends and consumer demands. Moreover, the value chain optimization and pricing strategy plays a crucial role as it enhance productivity and competitiveness & expansion respectively. Together, these elements set the stage for the market's sustained growth and leadership.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2024-2036 |
|
CAGR |
~7% |
|
Base Year Market Size (2023) |
~ USD 3 Billion |
|
Forecast Year Market Size (2036) |
~ USD 6 Billion |
|
Regional Scope |
|
Product (Plasma Derived, VWF Complex, Recombinant Antihemophilic Factor)
The recombinant antihemophilic factor offering products such as recombinant in single-dose vials with 250 to 2000 international units, is estimated to hold 63% share of the global antihemophilic factor market by 2036. The vials, when reconstituted, include stabilizers like human albumin, calcium, and polyethylene glycol, contributing to the segment’s growth. The co-expression of Recombinant von Willebrand factor (rVWF) with human recombinant FVIII (rFVIII) containing no more than 2ng rVWF, having no significant effect on von Willebrand disease, thereby ensuring efficacy and safety. This technological sophistication is expected to bolster market dominance, particularly in regions with growing healthcare infrastructure and patient awareness.
Distribution (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The retail pharmacies segment in the antihemophilic factor market is poised to secure the largest revenue share of 57% by 2036. This dominance is largely due to the substantial patient engagement these outlets experience, which is expected to drive sales of leading antihemophilic factors such as NovoSeven and FEIBA, which have historically reached USD 2 billion and USD 800 million in sales respectively. The ultimate investments by manufacturers in targeted genetic mutation therapies contribute to the growth, fostering a robust pipeline of innovative products that bolster the segment's expansion.
Our in-depth analysis of the global antihemophilic factor market includes the following segments:
|
Type |
|
|
Product |
|
|
Distribution |
|
North American Market Forecast
The North America antihemophilic factor market is anticipated to hold the largest share of about 53% by the end of 2036. The market growth in the region is expected on account of a robust healthcare system, substantial investment in research and development, and the presence of leading pharmaceutical companies focused on innovative therapies for hemophilia. The region’s strong regulatory frameworks and supportive policies for biologics and advanced drug therapies are contributing factors to its dominant position. Furthermore, the rapid growth of the over 65% population in the United States, with its increased adoption of medicare advantage, could account for this change, projecting an increase from 44% in 2021 to about 54% penetration in the medicare population by 2030. Additionally, the improved profitability of managed Medicaid, due to more coordinated and integrated care, is likely to further enhance the market growth prospects.
European Market Analysis
The Europe antihemophilic factor market is estimated to be the second largest, registering a share of about 24% by the end of 2036. The market’s growth is bolstered by high treatment-seeking rates, boosted by heightened awareness of hemophilia, well-established treatment protocols, and active patient organizations. Additionally, the region benefits from a sophisticated biotechnology sector and strategic partnerships between domestic and global pharmaceutical firms. Economic considerations also play a pivotal role, with the cost of severe hemophilia in five European countries reaching 2 billion in 2014, translating to nearly USD 300,000 per patient annually. With Germany bearing the highest per-patient costs at USD 300,000 and the UK, at the lower end at USD 200,000, the financial implications are vast and influence drug development and healthcare policy decisions across Europe’s diverse regions.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?